Pharmacokinetic and pharmacodynamic considerations on the erythropoietin effect and adverse events of darbepoetin-Reference-Cited by-同舟云学术

Pharmacokinetic and pharmacodynamic considerations on the erythropoietin effect and adverse events of darbepoetin

Published:2014-12-03 Issue:1 Volume:11 Page:139-147
ISSN:1742-5255
Container-title:Expert Opinion on Drug Metabolism & Toxicology
language:en
Short-container-title:Expert Opinion on Drug Metabolism & Toxicology

Author:

Keller Frieder¹,Ludwig Ulla¹,Czock David²

Affiliation:

1. 1University Hospital, Center for Internal Medicine, Department Innere 1, Nephrology, Albert-Einstein-Allee 23, D-89070 Ulm, Germany ; ;

2. 2University Hospital Heidelberg, Department of Clinical Pharmacology and Pharmacoepidemiology, Medizinische Klinik (Krehl-Klinik), Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany

Publisher

Informa Healthcare

Subject

Pharmacology,Toxicology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1517/17425255.2015.989832

Reference38 articles.

1. An expert opinion on the current treatment of anemia in patients with kidney disease

2. A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

3. Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes

4. Stroke in Patients With Type 2 Diabetes Mellitus, Chronic Kidney Disease, and Anemia Treated With Darbepoetin Alfa

5. Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Pharmacokinetics and Pharmacodynamics of Roxadustat;Clinical Pharmacokinetics;2021-12-14

2. The Combination of Cell Cultured Technology and In Silico Model to Inform the Drug Development;Pharmaceutics;2021-05-12

3. Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease;Nephrology Dialysis Transplantation;2020-08-23

4. Will there still be a role for the originator erythropoiesis-simulating agents after the biosimilars and the hypoxia-inducible factor stabilizers approval?;Current Opinion in Nephrology and Hypertension;2018-09

5. Optimizing the use of darbepoetin-α with a split strategy: A concept change;Clinical Nephrology;2018-02-01